Stryker Corporation (SYK)
Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
Stryker (SYK) came out with quarterly earnings of $4.47 per share, beating the Zacks Consensus Estimate of $4.4 per share. This compares to earnings of $4.01 per share a year ago.
SYK's Q4 Results Likely to Reflect Procedure Growth and Capital Demand
Stryker's fourth-quarter results are expected to highlight resilient procedure volumes and strong capital demand, supported by product momentum and broad-based strength.
Here's Why Stryker (SYK) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gear Up for Stryker (SYK) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker
Stryker offers above-average revenue growth, robust margin leverage, and a compelling valuation relative to med-tech peers despite sector-wide derating risks. Key growth drivers include Mako's continued share gains in major joints, expansion into extremities, and under-tapped potential in ambulatory surgical centers. Management prioritizes M&A for capital allocation, targeting complementary technologies in robotics, cardiology, and urology, while organic growth opportunities like Smart Care add upside.
Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
Why Stryker (SYK) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Stryker (SYK) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Are Insiders Are Dumping Shares of Robinhood, Stryker, and Mercury Systems?
Over $500 million in insider stock sales have hit three high-profile companies this month—an unsettling signal that even top executives and major stakeholders may be questioning the sustainability of recent gains.
Stryker Corporation (SYK) Analyst/Investor Day Transcript
Stryker Corporation ( SYK ) Analyst/Investor Day November 13, 2025 2:30 PM EST Company Participants Jason Beach - Vice President of Finance & Investor Relations Kevin Lobo - Chairman, CEO & President Spencer Stiles - Group President of Orthopaedics Dylan Crotty - President of Instruments Kathy Truppi J. Pierce - Group President of MedSurg & Neurotechnology Tim Lanier Viju Menon - Group President of Global Quality & Operations Debra King - VP, Chief Digital & Information Officer Jessica Mathieson Preston Wells - VP & CFO Conference Call Participants Neal Patel Robert Marcus - JPMorgan Chase & Co, Research Division Matthew Miksic - Barclays Bank PLC, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Travis Steed - BofA Securities, Research Division Ryan Zimmerman - BTIG, LLC, Research Division Pito Chickering - Deutsche Bank AG, Research Division Christopher Pasquale - Nephron Research LLC Joanne Wuensch - Citigroup Inc., Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Joshua Jennings - TD Cowen, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Conversation Jason Beach Vice President of Finance & Investor Relations Good afternoon.
Stryker: Strong Growth, But Valuation Is A Concern
Stryker (SYK) delivered strong Q3 2025 results, raising full-year guidance on robust organic growth across both MedSurg & Neurotechnology and Orthopaedics segments. SYK achieved double-digit organic sales and EPS growth, supported by margin expansion and successful product launches. Despite operational strength, SYK trades at a significant valuation premium to sector peers, with a PEG ratio above 2 and earnings growth in line with the S&P 500.
